In the phase III DESTINY-Breast02 trial, T-DXd demonstrated a significant PFS benefit in the third-line setting after disease progression with T-DM1 when compared to the combination of capecitabine and lapatinib or capecitabine and trastuzumab in HER2+ breast cancer [14]. The gene discussed is ERBB2; the disease is breast carcinoma.